Table 1.
Associations of clinical indicators and GLIS2 expression level with total survival in training data.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR | P values | HR | P values | |
| Radiotherapy | ||||
| Yes | 0.458(0.247-0.849) | 0.013 | 0.453(0.226-0.909) | 0.026 |
| No | 1.000 | 1.000 | ||
| Gender | ||||
| Male | 1.422(0.886-2.283) | 0.145 | 1.645(0.994-2.724) | 0.053 |
| Female | 1.000 | 1.000 | ||
| Age | ||||
| >60 | 1.498(0.894-2.509) | 0.125 | 1.569(0.895-2.751) | 0.116 |
| ≤60 | 1.000 | 1.000 | ||
| Histologic type | ||||
| NOS | 0.956(0.556-1.641) | 0.868 | 0.969(0.550-1.706) | 0.912 |
| DT/MT/SRT | 0.774(0.405-1.480) | 0.438 | 0.724(0.356-1.473) | 0.373 |
| PT/TT | 1.000 | 1.000 | ||
| T Stage | ||||
| T3/T4 | 1.891(1.088-3.285) | 0.024 | 1.642(0.870-3.098) | 0.126 |
| T1/T2 | 1.000 | 1.000 | ||
| N Stage | ||||
| N1/N2/N3 | 1.837(1.086-3.105) | 0.023 | 1.433(0.666-3.080) | 0.357 |
| N0 | 1.000 | 1.000 | ||
| M Stage | ||||
| M1 | 3.178(1.616-6.250) | 0.001 | 3.305(1.435-7.614) | 0.005 |
| M0 | 1.000 | 1.000 | ||
| Pathological stage | ||||
| III/IV | 1.810(1.129-2.902) | 0.014 | 1.268(0.609-2.639) | 0.526 |
| I/II | 1.000 | 1.000 | ||
| Targeted therapy | ||||
| Yes | 0.753(0.481-1.176) | 0.212 | 1.010(0.352-2.898) | 0.986 |
| No | 1.000 | 1.000 | ||
| Chemotherapy | ||||
| Yes | 0.771(0.497-1.196) | 0.246 | 0.792(0.291-2.160) | 0.649 |
| No | 1.000 | 1.000 | ||
| GLIS2 expression | ||||
| High | 1.232(0.794-1.910) | 0.352 | 1.353(0.854-2.144) | 0.197 |
| Low | 1.000 | 1.000 | ||
Note: HR: hazard ratio; NOS: not otherwise specified; DT: diffuse type; MT: mucinous type; SRT: signet ring type; PT: papillary type; TT: tubular type.